Metopirone (metyrapone) safely and successfully maintained lower levels of urinary cortisol over nine months in adults with endogenous Cushing’s syndrome, according to data from the six-month extension of the PROMPT trial. Treatment with the HRA Pharma Rare Diseases…
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Isturisa (osilodrostat) to treat people with endogenous Cushing’s syndrome for whom pituitary brain surgery has not been effective or is not an option. Recordati…
Biomarkers in a majority of Cushing’s syndrome patients with surgically induced disease remission showed a high rate of bone turnover and greater bone mineral density one and two years later, a study reports. Before treatment, these patients were found to have greater bone degradation…
A 67-year-old woman developed bone cancer 30 years after receiving radiation therapy to treat Cushing’s disease, according to a case report. Although the risk of bone cancer after radiation therapy is very low, this case highlights the need for long-term follow-up…
An alternative diagnostic test to measure the levels of late-night cortisol in the saliva of patients with Cushing’s disease did not meet the standards of currently used methods, a study demonstrates. The study, “Prospective evaluation of…
Abnormal fat accumulation, including increased bone marrow fat and insulin resistance, can lead to bone loss and a greater likelihood of fractures in people with Cushing’s disease, researchers report. Their study, “Beyond the…
Get regular updates to your inbox.